Coronavirus infection is considered a multifactorial disease; nevertheless, thrombotic complications play an important role in the further prognosis in this category of patients. More than 20 studies have been conducted around the world that have evaluated the optimal thromboprophylaxis regimens in hospitalized patients with COVID-19. Before prescribing antithrombotic therapy, it is necessary to conduct a comprehensive assessment of the parameters of the blood coagulation system. Of course, in all cases of chronic diseases, especially in the elderly, careful monitoring of clinical symptoms and the hemostasis system is required. The data of our study indicate the possibility of using rivoraxaban and acetylsalicylic acid in prophylactic doses in the absence of the need to adjust doses and drug regimens in patients with moderate to severe COVID-19.

Coronavirus infection, antithrombotic therapy, rivaroxaban,

Yavelov, I. S. COVID-19: the state of the hemostasis system and features of antithrombotic therapy. / I. S. Yavelov, O. M. Drapkina. // Cardiovascular therapy and prevention. 2020;9:310–318.

Simes, J. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. / Simes J., Becattini C., Agnelli G., Eikelboom J.W., Kirby A.C., Mister R. et al. // Circulation. 2014;130(13):1062–1071.

Jackson, S.P. Thromboinflammation: Challenges of Therapeutically Targeting Coagulation and other Host Defence Mechanisms. / Jackson S.P., Darbousset R., Schoenwaelder S.M. // Blood. 2019;133(9):906–918.

Bikdeli, B. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. / Bikdeli B., Madhavan M., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. // Journal of the American College of Cardiology. 2020;75(23):2950–2973.